PPD hires FDA, Novartis and Genentech veteran in new dual role

Jonca Bull has seen a series of regulatory roles across biopharma and FDA.

PPD has taken on the former assistant commissioner and director of its Office of Minority Health at the FDA, Jonca Bull, M.D., as VP of PPD Consulting, as well as vice president of ophthalmology, within global product development.

Using her experience at the FDA as well as her stints at Novartis and Genentech, Bull will help run PPD’s consulting unit and its regulatory side. The business provides full drug development design and planning facilities.

The company's global product development teams, meanwhile, will coordinate a variety of services and insight from therapeutic thought leaders to create customized development strategies to meet client needs.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Jonca possesses a wealth of experience in the regulatory arena, including with the FDA and in the pharmaceutical industry,” said Rob Dow, chief medical officer for PPD.

“Her experience working closely with pharmaceutical clients, as well as health and regulatory authorities, will help enhance patient engagement for PPD clients in developing life-changing therapies.”

Suggested Articles

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.